We maintain two active business segments: Specialized BioTherapeutics and Public Health Solutions. Our Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte™ (a proposed proprietary name of SGX301 or synthetic hypericin sodium), a novel photodynamic therapy (“PDT”), utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (“CTCL”).
Partnerships FDA Orphan Products Development grant-funded investigator-initiated study wound down Jun 2026 with the program.
Indications
Cutaneous T-cell lymphoma (CTCL)(Stage not disclosed)
Status note Photodynamic therapy for CTCL evaluated in the Phase 3 FLASH2 study. The DMC's Apr 2026 interim efficacy analysis recommended halting for futility; the Board terminated the HyBryte development program in Jun 2026 and is winding down the trial.
Status note Synthetic hypericin for psoriasis; company plans to conduct a Phase 2a clinical trial following positive proof-of-concept in a small Phase 1/2 pilot study in mild-to-moderate psoriasis patients.
Status note Dusquetide for aphthous ulcers in Behçet's Disease; company plans to conduct a Phase 2 clinical trial following prior studies validating biologic activity.
Partnerships Company seeking partner(s) to continue development.
Indications
Oral mucositis in head and neck cancer(Phase 3)
Status note Dusquetide for oral mucositis in head and neck cancer. Following UK MHRA feedback that a second Phase 3 trial would be required to support marketing authorization, the company plans to design a second study and identify partner(s) to continue the program.
Public Health Solutions vaccine programs
Stage not disclosed · ActiveModality: vaccine (ThermoVax heat-stabilized)
Partnerships Supported by government grant/contract funding from NIAID, BARDA and the Defense Threat Reduction Agency.
Indications
Ricin toxin exposure (vaccine)(Stage not disclosed)
Filoviruses (Marburg, Ebola) (vaccines)(Stage not disclosed)
Status note Public Health Solutions segment includes RiVax (ricin toxin vaccine candidate) and filovirus vaccine programs (Marburg, Ebola) using the proprietary ThermoVax heat stabilization platform. Clinical phases not disclosed in the excerpts.
Per-asset detail extracted from the 10-Q filed 2026-08-07. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
Specialist fund holders
Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.
None of the tracked specialist funds reported a position in the latest 13F snapshot.
Latest news
Loading headlines…
Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 718 stocks.